Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration

by Business Wire • 2020/01/09 • 0 Comments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics has enrolled the first patient in its Phase 1 study of GEM103 for dry age-related macular degeneration.

← New method for fabricating collagen fibrils facilitates research on the eye’s repair process

Researchers identify ways to improve physician-patient visits →

Post navigation